RESUMEN
Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are n-3 polyunsaturated fatty acids (PUFAs), and are abundant in fish oil. These n-3 PUFAs have been reported to improve the lower gastrointestinal (LGI) disorders such as ulcerative colitis and Crohn's disease through their anti-inflammatory effects. However, there are few studies on the effect of n-3 PUFAs on motility of the LGI tract, such as the ileum and colon, the parts frequently affected by these inflammatory disorders. To elucidate the effects of DHA and EPA on the LGI tract motility, we performed comparative evaluation of their effects and linoleic acid (LA), an n-6 PUFA, on contractions in the ileal and colonic longitudinal smooth muscles (LSMs) isolated from guinea pigs. In the ileal and colonic LSMs, DHA and EPA (3 × 10-5 M each) significantly inhibited contractions induced by acetylcholine (ACh), histamine, and prostaglandin (PG) F2α (vs. control), and these effects are stronger than that of LA (3 × 10-5 M). In the colonic LSMs, DHA and EPA also significantly inhibited contractions induced by PGD2 (vs. control). In addition, DHA and EPA significantly inhibited CaCl2-induced ileal and colonic LSM contractions in Ca2+-free 80 mM-KCl solution (vs. control). Any ileal and colonic LSM contractions induced by ACh, histamine, PGF2α, and CaCl2 were completely suppressed by verapamil (10-5 M), a voltage-gated/dependent Ca2+ channel (VGCC/VDCC) inhibitor. These findings suggest that DHA and EPA could improve the abnormal contractile functions of the LGI tract associated with inflammatory diseases, partly through inhibition of VGCC/VDCC-dependent ileal and colonic LSM contractions.
Asunto(s)
Colon/efectos de los fármacos , Ácidos Docosahexaenoicos/farmacología , Ácido Eicosapentaenoico/farmacología , Motilidad Gastrointestinal/efectos de los fármacos , Íleon/efectos de los fármacos , Contracción Muscular/efectos de los fármacos , Músculo Liso/efectos de los fármacos , Acetilcolina , Animales , Canales de Calcio/metabolismo , Tracto Gastrointestinal/efectos de los fármacos , Cobayas , Histamina , Inflamación , Enfermedades Intestinales/metabolismo , Enfermedades Intestinales/fisiopatología , Ácido Linoleico/farmacología , Masculino , Músculo Liso/metabolismo , Músculo Liso/fisiología , ProstaglandinasRESUMEN
Naldemedine (NAL), a peripherally acting µ-opioid receptor antagonist, is effective for opioid-induced constipation (OIC). However, diarrhea is the most common adverse event. We investigated the incidence of NAL-induced diarrhea in patients who started NAL at Nagasaki University Hospital between June 2017 and March 2019. Predictors of NAL-induced diarrhea were analyzed using a multivariate logistic regression model. Two hundred and forty-two patients were included in the present study, and NAL-induced diarrhea was observed in 17.8% (43 patients). The results of multiple logistic regression analyses identified the administration of opioid analgesics for 8 d or longer before the initiation of NAL (odds ratio (OR): 2.20, 95% confidence interval (95% CI): 1.04-4.64, p = 0.039), the combination of a laxative (OR: 2.22, 95%CI: 1.03-4.81, p = 0.042), and the combination of CYP3A4 inhibitors (strong/moderate) (OR: 2.80, 95%CI: 1.02-7.67, p = 0.045) as risk factors. Therefore, the development of diarrhea needs to be considered in patients with these risk factors. Furthermore, diarrhea may be controlled by the initiation of NAL within 7 d of opioid analgesics and, where possible, the discontinuation of or change in the combination of moderate or strong CYP3A4 inhibitors.
Asunto(s)
Estreñimiento/tratamiento farmacológico , Diarrea/inducido químicamente , Naltrexona/análogos & derivados , Antagonistas de Narcóticos/efectos adversos , Anciano , Analgésicos Opioides/efectos adversos , Estreñimiento/inducido químicamente , Inhibidores del Citocromo P-450 CYP3A/efectos adversos , Femenino , Humanos , Laxativos/efectos adversos , Modelos Logísticos , Masculino , Persona de Mediana Edad , Naltrexona/administración & dosificación , Naltrexona/efectos adversos , Naltrexona/uso terapéutico , Antagonistas de Narcóticos/administración & dosificación , Antagonistas de Narcóticos/uso terapéutico , Oportunidad Relativa , Receptores Opioides mu/antagonistas & inhibidores , Factores de RiesgoRESUMEN
As a new alternative to antibody-drug conjugates, we generated "ligand-targeting" peptide-drug conjugates (PDCs), which utilize receptor-mediated endocytosis for targeted intracellular drug delivery. The PDC makes a complex with an extracellular ligand and then binds to the receptor on the cell surface to stimulate intracellular uptake via the endocytic pathway. A helix-loop-helix (HLH) peptide was designed as the drug carrier and randomized to give a conformationally constrained peptide library. The phage-displayed library was screened against vascular endothelial growth factor (VEGF) to yield the binding peptide M49, which exhibited strong binding affinity (KD = 0.87 nM). The confocal fluorescence microscopy revealed that peptide M49 formed a ternary complex with VEGF and its receptor, which was then internalized into human umbilical vein endothelial cells (HUVECs) via VEGF receptor-mediated endocytosis. The backbone-cyclized peptide M49K was conjugated with a drug, monomethyl auristatin E, to afford a PDC, which inhibited VEGF-induced HUVEC proliferation. HLH peptides and their PDCs have great potential as a new modality for targeted molecular therapy.
Asunto(s)
Aminobenzoatos/administración & dosificación , Portadores de Fármacos/metabolismo , Oligopéptidos/administración & dosificación , Péptidos/metabolismo , Factor A de Crecimiento Endotelial Vascular/metabolismo , Aminobenzoatos/química , Aminobenzoatos/farmacocinética , Aminobenzoatos/farmacología , Proliferación Celular/efectos de los fármacos , Portadores de Fármacos/química , Sistemas de Liberación de Medicamentos , Endocitosis , Células Endoteliales de la Vena Umbilical Humana , Humanos , Oligopéptidos/química , Oligopéptidos/farmacocinética , Oligopéptidos/farmacología , Biblioteca de Péptidos , Péptidos/químicaRESUMEN
Opioid-induced-constipation (OIC) can be treated by naldemedine and other peripherally acting mu-opioid receptor antagonists (PAMORA) via a novel mechanism. We describe the case of a 52-year-old female outpatient who developed OIC while receiving oxycodone for pain due to cancer with multiple bone metastases. Although she did not have brain metastasis, opioid withdrawal syndrome (OWS) developed after taking naldemedine orally. Her Clinical Opiate-Withdrawal Score (COWS) was 19 (moderate symptoms). However, she recovered from OWS on intravenous fentanyl and a continuous infusion of oxycodone. She did not develop OWS thereafter and was discharged two days after recovery.
Asunto(s)
Naltrexona/análogos & derivados , Antagonistas de Narcóticos/efectos adversos , Estreñimiento Inducido por Opioides/tratamiento farmacológico , Oxicodona/efectos adversos , Síndrome de Abstinencia a Sustancias/etiología , Analgésicos Opioides/uso terapéutico , Neoplasias de la Mama/patología , Dolor en Cáncer/tratamiento farmacológico , Femenino , Humanos , Persona de Mediana Edad , Naltrexona/efectos adversos , Naltrexona/uso terapéutico , Antagonistas de Narcóticos/uso terapéutico , Oxicodona/uso terapéutico , Síndrome de Abstinencia a Sustancias/tratamiento farmacológicoRESUMEN
A series of ethyl 4-(2-aryloxyhexyloxy)benzoates was prepared and tested for their activity to induce precocious metamorphosis in larvae of the silkworm. Phenyl analog 5 showed activity comparable to that of the 6-methyl-3-pyridyl analog reported as a novel anti-JH agent. The activity of 5 could be fully counteracted by methoprene, a JH agonist. The ethoxycarbonyl group of 5 was essential for its activity.